Enrolled in registry (n=7867)

Cancer-related pain patients (n=1439)

Patients with other treatment indications (n=6428)

* Non-cancer-related pain (n=4545)
* Spasticity (n=1714)
* Combination non-cancer pain and spasticity (n=101)
* Unknown (n=69)

Implanted (n=1403)

Not implanted (n=36)

Active in registry post-2010 (n=706)

Enrolled in registry post-2010 and pain score collected at baseline (n=283)

Exited from registry before 2010 (n=697)

6-month pain score collected (n=103)

12-month pain score collected (n=55)

Enrolled in registry post-2013 and EQ-5D score collected at baseline (n=142)

6-month EQ-5D collected (n=41)

12-month EQ-5D collected (n=27)

**Supplementary Figure 1. Analysis Sets within the Registry**

**Registry Protocol Amendments and Analysis Sets**

Data collection in the registry has evolved from its initiation in 2003, resulting in differences in data availability based on patient enrollment date and follow-up periods. The key protocol revisions resulting in different analysis sets are:

* 2003 to Current
	+ All-cause mortality, device performance, and adverse events requiring surgical interventions on the implanted system have been consistently collected throughout the duration of the registry.
		- All implanted patients were included in analyses of these outcomes (n=1403).
* 2010 to Current
	+ Adverse event collection was expanded to all serious adverse events
		- All patients implanted and in active follow-up during this period (n=706)
	+ Pain assessment was added to the registry
		- Patients in follow-up during this period provide Pain Scores
		- Only patients enrolled (with their initial pump) provide usable baseline data (n=283)
			* Patients with Pain Scores at baseline and 6 months (n=103) or 12 months (n=55) were included in the analysis of change in pain
* 2013 to Current
	+ The EQ-5D-5L assessment of Quality of Life was added to the registry
		- Patients in follow-up during this period provide EQ-5D outcomes
		- Only patients enrolled (with their initial pump) provide usable baseline data (n=142)
			* Patients with EQ-5D-5L at baseline and 6 months (n=41) or 12 months (n=27) were included in the analysis of change in EQ-5D